SCHEMBL6757236

SCHEMBL6757236

CCOc1cn(C(C)c2ccccc2)c(=O)o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.42
MET P08581 5/20 0.42
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
GABRA1 P14867 2/20 0.40
GABRB2 P47870 2/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
LMNA P02545 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ABCB11 O95342 1/20 0.40
GABRA2 P47869 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MGLL Q99685 2/20 0.36
BRD4 O60885 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759730 0.89 MET (0.40) FAAHMETCYP1A2CYP3A4GABRA1
SCHEMBL6759698 0.88 MET (0.39) FAAHMETCYP1A2CYP3A4GABRA1
SCHEMBL6761258 0.87 GAA (0.39) FAAHMEN1KMT2AMGLL
SCHEMBL6762431 0.86 MET (0.43) FAAHMETLMNAMEN1KMT2A
SCHEMBL4676274 0.84 FAAH (0.51) FAAHMETMEN1KMT2AHPGD
SCHEMBL4679478 0.84 FAAH (0.51) FAAHMETMEN1KMT2AHPGD
SCHEMBL4678109 0.82 FAAH (0.43) FAAHMETMEN1KMT2AHPGD
SCHEMBL4678103 0.82 FAAH (0.43) FAAHMETMEN1KMT2AHPGD
SCHEMBL4680402 0.81 FAAH (0.46) FAAHMETMEN1KMT2AHPGD
SCHEMBL6764349 0.81 FAAH (0.46) FAAHMETMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6723860-B2 7a-alkoxy-4H-pyrano[3,2-d]-oxazol-2(3H)-one and process for producing the same UBE INDUSTRIES, LTD. (JP) 2004-04-20 US disclosed
EP-1207162-B1 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same UBE INDUSTRIES (JP) 2004-02-25 EP disclosed
US-20020072612-A1 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same UBE INDUSTRIES, LTD. (JP) 2002-06-13 US disclosed
EP-1207162-A1 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same Ube Industries, Ltd. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072612-A1 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same ACSL1, ACSL4, ACSL3 FAAH 183/4885MET 2422/4885CYP1A2 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.